May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Nepafenac 0.1% for the Treatment of Cystoid Macular Edema
Author Affiliations & Notes
  • S. K. Patel
    Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas
  • J. Heffez
    Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas
  • P. E. Carvounis
    Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas
    Michael E. DeBakey Veterans Affairs Medical Center, Ophthalmology, Houston, Texas
  • A. C. Kopel
    Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas
  • E. R. Holz
    Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, Texas
  • Footnotes
    Commercial Relationships  S.K. Patel, None; J. Heffez, None; P.E. Carvounis, None; A.C. Kopel, None; E.R. Holz, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5628. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. K. Patel, J. Heffez, P. E. Carvounis, A. C. Kopel, E. R. Holz; Nepafenac 0.1% for the Treatment of Cystoid Macular Edema. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5628. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the short term visual outcomes following use of Nepafenac 0.1% for postoperative and uveitic cystoid macular edema (CME).

Methods: : Retrospective, comparative study of 18 eyes of 17 patients with CME who were treated with nepafenac 0.1%. The primary outcome was visual acuity 6 weeks after initiation of treatment.

Results: : There were 6 eyes with CME following cataract surgery treated with nevanac 1-5 months after surgery (mean 3.3 months): mean log MAR visual acuity improved from 0.68 (20/95) to 0.42 (20/53) which was highly statistically significant (p=0.0003). There were 9 eyes of 9 patients with CME following surgery other than cataract surgery: mean log MAR visual acuity was 0.83 (20/136) at baseline and worsened to 0.85 (20/143, p=0.85). In the 3 eyes with uveitic CME vision was 0.22 (20/34) at baseline and was 0.41 (20/52) after 6 weeks of nepafenac treatment (p=0.29).

Conclusions: : There is significant improvement in visual acuity following nepafenac treatment of CME related to cataract surgery although this may not be superior to that expected by natural history. Six week results of nepafenac treatment for CME secondary to uveitis or surgery other than cataract surgery are disappointing.

Keywords: edema • macula/fovea • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×